Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study | Zendy

Hiroshi Nakatsumi | Zendy; Yoshito Komatsu | Zendy; Satoshi Yuki | Zendy; Susumu Sogabe | Zendy; Miki Tateyama | Zendy; Shuichi Muto | Zendy; Mineo Kudo | Zendy; Kanji Kato | Zendy; Takuto Miyagishima | Zendy; Minoru Uebayashi | Zendy; Takashi Meguro | Zendy; Koji Oba | Zendy; Masahiro Asaka | Zendy

Open Access

Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study

Author(s) -

Hiroshi Nakatsumi,

Yoshito Komatsu,

Satoshi Yuki,

Susumu Sogabe,

Miki Tateyama,

Shuichi Muto,

Mineo Kudo,

Kanji Kato,

Takuto Miyagishima,

Minoru Uebayashi,

Takashi Meguro,

Koji Oba,

Masahiro Asaka

Publication year - 2012

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000345920

Subject(s) - nausea , vomiting , medicine , chemotherapy , randomized controlled trial , chemotherapy induced nausea and vomiting , anesthesia , pharmacology , surgery , antiemetic

Indisetron is a serotonin (5-hydroxytryptamine type 3) receptor antagonist that also antagonizes 5-hydroxytryptamine type 4 receptors. We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research